scPharmaceuticals (SCPH) said late Thursday the US Food and Drug Administration approved its supplemental new drug application to expand the use of Furoscix to treat edema in patients with chronic kidney disease.
The drug is expected to be available for chronic kidney disease patients in April, the company said.
Furoscix's use was previously limited as a treatment for edema in patients with chronic heart failure.
Shares of the company were up 5.2% in after-hours activity.
Price: 3.28, Change: +0.16, Percent Change: +5.21
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments